This communication aims to present m-RESIST, the first mHealth program for patients with treatment resistant schizophrenia (TRS). The main objective of this European project is to develop an intervention programme to allow TRS patients to self-manage their condition, which is associated with persistent positive symptomatology, extensive periods of hospital care, and a greater risk of excess mortality and multi-morbidity.

m-RESIST could offer a new tool for mental health professionals to better monitor TRS patients, providing a tailored and optimized therapeutic intervention. In this sense, m-RESIST will develop and validate a mHealth tool aimed to reduce the severity of episodes and further complications. Moreover, this tool will involve and promote a proactive role of patients and caregivers in the therapeutic process, promoting an active and collaborative role with the medical team in the treatment decision-making procedure.

m-RESIST intervention, will integrate: (1) a sensor data analysis module, which will process data coming from smart phone and wearable devices, providing passive information such as movement or social activity; (2) a predictive modeling engine, which will enable prediction of clinically significant events, such as hospitalization, risk behaviors and social isolation; and (3) a clinical decision support system (CDSS), which will provide the users with necessary information to support health-related and clinical decision-making.

The pilots of this project will take place in Tel-Aviv, Budapest and Barcelona during May, June and July of 2017. Although cost-effectiveness variables will also be measured, the main assessment will be focused on acceptability, usability, satisfaction, empowerment and quality of life outcomes.